CD8A and melanoma: A recent clinical trial conducted in patients with melanoma showed that vaccination with a long 30-mer peptide from NY-ESO-1, Montanide, and CpG-B is safe and well-tolerated and leads to CD4+ and CD8+ antigen-specific T cell responses.